Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PROK
Upturn stock ratingUpturn stock rating

ProKidney Corp. (PROK)

Upturn stock ratingUpturn stock rating
$0.59
Last Close (24-hour delay)
Profit since last BUY-34.34%
upturn advisory
SELL
SELL since 5 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: PROK (1-star) is a SELL. SELL since 5 days. Profits (-34.34%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $4.4

1 Year Target Price $4.4

Analysts Price Target For last 52 week
$4.4Target price
Low$0.46
Current$0.59
high$2.59

Analysis of Past Performance

Type Stock
Historic Profit -61.88%
Avg. Invested days 17
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.76B USD
Price to earnings Ratio -
1Y Target Price 4.4
Price to earnings Ratio -
1Y Target Price 4.4
Volume (30-day avg) 7
Beta 1.46
52 Weeks Range 0.46 - 2.59
Updated Date 06/29/2025
52 Weeks Range 0.46 - 2.59
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.59

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -17994.78%

Management Effectiveness

Return on Assets (TTM) -28.29%
Return on Equity (TTM) -45.28%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -235865660
Price to Sales(TTM) 5745.71
Enterprise Value -235865660
Price to Sales(TTM) 5745.71
Enterprise Value to Revenue -
Enterprise Value to EBITDA 2.13
Shares Outstanding 129536000
Shares Floating 78160800
Shares Outstanding 129536000
Shares Floating 78160800
Percent Insiders 30.05
Percent Institutions 41.88

Analyst Ratings

Rating 3
Target Price 4.4
Buy -
Strong Buy 4
Buy -
Strong Buy 4
Hold 3
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

ProKidney Corp.

stock logo

Company Overview

overview logo History and Background

ProKidney Corp., founded to develop cell therapies for chronic kidney disease (CKD), went public through a SPAC merger. Its focus is on regenerative medicine to slow or reverse kidney disease progression.

business area logo Core Business Areas

  • Cell Therapy Development: Developing REN-001, a proprietary cell therapy for CKD, designed to protect and potentially restore kidney function.

leadership logo Leadership and Structure

ProKidney has a management team with experience in cell therapy and nephrology. The organizational structure is focused on research, clinical development, and manufacturing of REN-001.

Top Products and Market Share

overview logo Key Offerings

  • REN-001: REN-001 is a cell therapy in clinical trials for diabetic kidney disease (DKD) and other forms of CKD. There is currently no market share as the product is still in trials. Competitors include companies developing drugs to manage CKD complications (e.g., dialysis providers, pharmaceutical companies targeting blood pressure or anemia).

Market Dynamics

industry overview logo Industry Overview

The CKD treatment market is large and growing, driven by aging populations, diabetes, and hypertension. It is currently dominated by dialysis and supportive care, with unmet needs for disease-modifying therapies.

Positioning

ProKidney aims to disrupt the CKD treatment paradigm with a regenerative cell therapy. It is positioned as a potential first-in-class treatment to slow or reverse disease progression.

Total Addressable Market (TAM)

The estimated TAM for CKD treatments is significant, potentially exceeding $100 billion annually. ProKidney is positioned to capture a portion of this market if REN-001 proves effective and gains regulatory approval.

Upturn SWOT Analysis

Strengths

  • First-in-class regenerative cell therapy approach
  • Proprietary technology platform
  • Experienced management team
  • Potential to address a large unmet medical need

Weaknesses

  • Clinical trial risk
  • Regulatory approval risk
  • Manufacturing complexity
  • High development costs
  • Relatively small company

Opportunities

  • Positive clinical trial results
  • Strategic partnerships with pharmaceutical companies
  • Expansion of REN-001 to other kidney diseases
  • Regulatory fast-track designations
  • Increasing prevalence of CKD

Threats

  • Failure of clinical trials
  • Regulatory delays or rejection
  • Competition from other CKD therapies
  • Adverse events associated with REN-001
  • Changes in reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • GILD
  • VRTX
  • LLY
  • NVO

Competitive Landscape

ProKidney's advantage lies in its regenerative cell therapy approach, which differentiates it from companies focused on managing CKD symptoms or slowing disease progression. The main disadvantage is the high risk and uncertainty associated with cell therapy development.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is limited as ProKidney is pre-revenue. Growth will depend on successful clinical development and commercialization of REN-001.

Future Projections: Future projections depend heavily on REN-001 clinical trial outcomes and regulatory approval. Analyst estimates vary widely, reflecting the inherent uncertainty of drug development.

Recent Initiatives: Recent initiatives include enrolling patients in Phase 3 clinical trials of REN-001 and securing additional funding.

Summary

ProKidney is a high-risk, high-reward company pursuing a novel approach to treating chronic kidney disease. Its success hinges on positive clinical trial outcomes for REN-001. The company has a strong scientific foundation and experienced management but faces significant regulatory and financial hurdles. Investors should monitor clinical trial progress and cash burn closely.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Industry publications
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual risk tolerance and due diligence.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About ProKidney Corp.

Exchange NASDAQ
Headquaters Winston-Salem, NC, United States
IPO Launch date 2022-07-12
CEO & Director Dr. Bruce Culleton M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 204
Full time employees 204

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.